CN1951395A - Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug - Google Patents
Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug Download PDFInfo
- Publication number
- CN1951395A CN1951395A CNA2006101320479A CN200610132047A CN1951395A CN 1951395 A CN1951395 A CN 1951395A CN A2006101320479 A CNA2006101320479 A CN A2006101320479A CN 200610132047 A CN200610132047 A CN 200610132047A CN 1951395 A CN1951395 A CN 1951395A
- Authority
- CN
- China
- Prior art keywords
- active component
- stem
- sweroside
- amounts
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a method for extracting and purifying active constituents from honeysuckle (Lonicera japonica Thunb.) and its use. More particularly, this invention relates to an extraction and purification method of active constituents including sweroside from for honeysuckle stem (stem of honeysuckle where leaves are removed) by removing tannins, hardly soluble flavonoids, saponins, and the like. Thus obtained active constituents have better anti-inflammatory and analgesic effect, are safer and more stable than the conventional active constituents obtained from honeysuckle flower or honeysuckle leaves, and include sweroside which is an effective active ingredient of anti-inflammatory and analgesic drug.
Description
The application is to be No. 8, in JIUYUE, 2003 applying date, and application number is 03823484.X, and the invention exercise question is divided an application for " extract from stem of Caulis Lonicerae and purification active component method, its application in antiinflammatory and analgesic ".
Invention field
The present invention relates to from Radix Ophiopogonis (Radix Ophiopogonis) to extract and the method and the application thereof of purification active component.In particular, the present invention relates to from stem of Caulis Lonicerae (having removed the stem of Caulis Lonicerae of leaf) to extract and purification comprises the method for the active component of sweroside, wait and carry out by removing tannin, slightly solubility flavonoid, saponarin.The active component commonly used that thus obtained active component obtains than from Flos Lonicerae or Folium Lonicerae has better antiinflammatory and analgesic effect, safer and more stable, and is included as the sweroside of the effective active component of antiinflammatory and analgesic.
Background of invention
Radix Ophiopogonis (Radix Ophiopogonis) is half evergreen part rattan shape shrub, and its spontaneous growth is in the mountain or the embankment underfooting of Japan, China and Korea S height above sea level 50-600 rice scope.Its alabastrum (Flos Lonicerae) and stem (stem of Caulis Lonicerae) as promote to urinate, the medical herbs of detoxifcation, hemostasis, blood purification, treatment tumor, treatment edema, flu, diarrhoea, vomiting etc.[explain Chang-Bok Lee, 709,1989, Hangmun Publishing Co., Seoul in Korea S's plant textbook; " medical herbs that Pharmacopoeia Coreana does not comprise (medical herbs) standard " (Standard for Herbs (Herb Medicines) Not Coveredby Korean Pharmacopoeia), Hyung-Joon Chi, Sang-In Lee, 87,305,1988, Korea Medical Index Co., Seoul; " Korea S's plant resources " (ResourcePlants in Korea), Tae-Kyung Kim, vol.4,148-149,1996, SNU Press, Seoul].In addition, many traditional Chinese medicine books, comprise and instructed it can treat inside and outside inflammatory abscess [the Sasang Constitutional Medicine for Chosun People of various human bodies well among Sasang ConstitutionalMedicine and the Gwangje Bigeup, Yenben Chosun Medical Institute, 276,1991, Yeogang PublishingCo., Seoul; Gwangje Bigeup, Kyung-Hwa Lee, 349-351,1991, YeogangPublishing Co., Seoul].Because of the active long-term medicine among the people of its anti-inflammatory analgesic as treatment such as this class upper respiratory tract infection of flu, tonsillitis and neuralgia.Recently, the antiinflammatory that confirmed Radix Ophiopogonis by various experimental animal models with analgesic activity and in academic scope, separated and reported its useful physiological active component [" research and development of plant anti-inflammatory agent: Radix Ophiopogonis the extract antiinflammatory and the comparison of analgesic effect " (Development of the vegetableanti-inflammatory medicine:Comparison of anti-inflammatory andanalgesic actions of the honeysuckle extract), Song-Jin Lee etc., " Korea S's pharmacognosy magazine " (Korean Journal of Pharmacognosy), 363-367,25,1994; " from the flavonoid of Radix Ophiopogonis aerial parts " (Flavonoids fromthe aerial parts of Lonicera japonica), Son etc., " drug research journal " (Arch.Pharm.Res.), 365-370,15,1992; " anti-inflammatory activity of Radix Ophiopogonis " (Antiinflammatory activity of Lonicera japonica), Lee etc., " phytotherapy research " (Phytother.Res.), 445-447,12,1998; " from the triterpenoid ZAOCAO glycoside of Radix Ophiopogonis aerial parts " (Triterpenoids aponins from theaerial parts of Loiiiceia japonica), Son etc., " phytochemistry " (Phytochem.), 1005-1008,35,1994; The anti-inflammatory activity of main component " Radix Ophiopogonis " (Anti-inflammatory activity of the major constituents ofLonicera japonica), Lee etc., " drug research journal " (Arch.Pharm.Res.), 133-135,18,1995].
The description of association area
Up to now, be called the effective active composition that contains in the stem of Caulis Lonicerae such as the hydrolyzable tannin of this class of chlorogenic acid, caffeic methyl ester, chlorogenic acid and isochlorogenic acid with such as this class iridoid glycosides of loganin, sweroside, vogeloside and epi-vogeloside.Most of conventional study concentrates on Flos Lonicerae and the Folium Lonicerae.Should notice that stem of Caulis Lonicerae has the component distributing that is different from Folium Lonicerae or Flos Lonicerae.Promptly be different from stem of Caulis Lonicerae, the main component of Folium Lonicerae or Flos Lonicerae is: flavonoid, such as xylostein, Radix seu Folium Tosicodendri Delavayi glucoside and chain genitein; Have hederagenin or oleanolic acid triterpene saponarin as non-sugar ingredient; With various hydrolyzable tannin.
Be difficult to these compositions are made injection.If injection is rich in the polymer tannin, they can combine with other composition and produce co-precipitation and can form the slightly solubility precipitation in conjunction with the serum albumin in the blood so, and this may be the reason of angiostenosis.In addition because the flavonoid that comprises is generally water insoluble in Radix Ophiopogonis, so requisite be they to be dissolved to the level that is higher than valid density with quite a large amount of organic solvents or other reagent as the dissolving amboceptor.In addition, be insoluble in the injection normal saline solution and, may become unstable so if be rich in the active component utmost point of flavonoid in the medium-term and long-term storage of alkaline buffer solution.At last, known have strong haemolysis available from the saponarin of Radix Ophiopogonis, particularly Monodesmosidic Saponins (monodesmosides).Therefore, can not they are purified and directly inject the vein [research of saponarin " relevant Radix Ophiopogonis " (Studies on thesaponins of Lonicera japonica Thunb.), Kawai etc., " pharmaceutical chemistry bulletin " (Chem.Pharm.Bull.), 4769-4775,36 (12), 1988].The tannin of Folium Lonicerae and Flos Lonicerae and slightly solubility flavonoid content are higher than stem of Caulis Lonicerae.In the injection acute toxicity test, it is relatively poor that more toxicity and the pain relieving that provides and antiinflammatory action also can be provided under low content for they.
Radix Ophiopogonis, Swertia japonica, Radix Gentianae, three flower Radix Gentianae, bar leaf Radix Gentianae, Gentiana rigescens Franch, some flower Yunnan Radix Gentianae are used to alleviate generate heat or detoxify many years.Yet, be not expressly understood that the activity which composition can provide this class effect and most of research and concentrate on the main medicinal ingredient loganin of identifying stem of Caulis Lonicerae [" natural product magazine " (J.Nat.Prod.), 54 (4), 1102-1104,1991: " plant amedica " (Planta Med.), 60,232-234,1994: " phytotherapy research " (Phytotherapy Res.), 12,405-408,1998].
In addition, think sweroside only protect the liver effectively and suppress bacterial activity [" ethnopharmacology magazine " (Ethnopharmacol.), 42,183-191,1994: " (the pharmaceutical chemistry bulletin " (Chem.Pharm.Bull.), 45 (11), 1823-1827,1997:Yakugaku Zasshi, 102 (8), 755-759,1982], and do not report its antiinflammatory and analgesic effect up to now as yet.
Summary of the invention
The present inventor has determined to remove the active component (having removed the stem of Caulis Lonicerae of leaf) of stem of Caulis Lonicerae of tannin, slightly solubility flavonoid, saponarin etc. and the effective active composition sweroside in the described active component has good antiinflammatory and analgesic effect.
Therefore, an object of the present invention is to provide the method that from stem of Caulis Lonicerae, prepares active component with good antiinflammatory and analgesic activity, safety and stability.
Another object of the present invention provides antiinflammatory and the analgesic that comprises described active component.
Another object of the present invention provides antiinflammatory and the analgesic that comprises sweroside.
The accompanying drawing summary
Accompanying drawing 1 is the sketch map of expression with the active ingredient medicine effect of content change.
Detailed description of the preferred embodiments
The invention provides the method that from honeysuckle stem preparation has the active component of good anti-inflammatory and analgesic activity, safety and stability.
The present invention also provides anti-inflammatory and the anodyne that comprises described active component.
The present invention also provides anti-inflammatory and the anodyne that comprises described sweroside.
Hereinafter provided detailed description of the present invention.
The present invention relates to from Radix Ophiopogonis to extract and the method for purification active component and sweroside, wait and carry out by removing tannin, slightly solubility flavonoid, saponarin.The active component commonly used that thus obtained active component obtains than from Flos Lonicerae or Folium Lonicerae has better antiinflammatory and analgesic effect, safer and more stable and be included as the sweroside of the effective active component of antiinflammatory and analgesic.From stem of Caulis Lonicerae, extract active component and sweroside also by following method purification.
Distilled water with about 7-10 volume extracts the stem of Caulis Lonicerae back flow of sample 2-3 hour and filters then.The distilled water reflux, extract, of a collection residue and the about 5-7 of usefulness volume 2-3 hour.Filter thus obtained liquid and merge, under reduced pressure, concentrate and filter once more, make 1-3 that its volume is about medical herbs weight doubly (v/w) with above-mentioned filtrate.With in the process of distilled water extraction,, stir to become difficulty and extraction efficiency so and will reduce, because the dissolubility variation of extract if the distilled water that uses is very few.On the contrary, if use excessive distilled water, time that needs so and cost will be too high.Therefore, add the water saturated lower alcohol of equivalent and under 30-50rpm stir about 10-20 minute.After layer separates, filter water saturated lower alcohol layer and under reduced pressure, concentrate and obtain the primary activity composition.In this article by distilled water being joined such as also stirring, sedimentation subsequently prepare water saturated lower alcohol in propanol and this class lower alcohol of butanols.Layer separation process carried out 2-3 time.In the process that obtains the lower alcohol solvent fraction, if the lower alcohol that uses is very few, purification efficiency will reduce so, extracts productive rate and active constituent content thus and reduces.On the contrary, if use too much lower alcohol, cost is increased.Therefore, the lower alcohol of volume (v/w) as 1-3 times of medical herbs weight used in suggestion.
Use polyamide, polyvinylpyrrolidone resin etc. that the primary activity composition is carried out column chromatography to remove unwanted material and to detect active component.In the water saturated lower alcohol layer of 1-10 volume (w/w), use filler.50% (v/v) methanol of an eluting 2-3 volume and methanol and packing volume and then by substep gradient method eluting distilled water solvent.Contain aromatics organic acid, tannin and flavonoid still less and show the dissolubility of drug effect, significantly reduced toxicity, increase preferably and the blood stability of improvement by the secondary active component that obtains with distilled water eluting active component.Use (octadecylsilane) resin that the secondary active component is carried out column chromatography again.Since 10% (v/v) methanol,, simultaneously methanol content is increased by 10% (v/v) by the solvent resin volume of 2-3 volume of substep gradient method eluting.Use polyamide or polyvinylpyrrolidone resin as the 20-50 times of volume of primary activity composition weight of purification.The active component that obtains by eluting 20-30% (v/v) methanol shows best antiinflammatory and analgesic activity.Analysis to these active component discloses the iridoids material, be main active component such as sweroside and loganin.Sweroside content is that 15.1-72.1wt% and loganin content are 13.9-41.4wt%.
The active component that obtains by eluting 20-30% (v/v) methanol has the highest sweroside content.Again these active component are carried out column chromatography to separate the sweroside of being represented by following chemical formula 1:
The active component that obtains thus and sweroside are carried out dropsy of ear test that dropsy of ear test that arachidonic acid brings out and Oleum Tiglii brings out with the mensuration antiinflammatory action.And carry out writhing test that acetic acid brings out to measure analgesic effect.Found that they have antiinflammatory and the analgesic activity that is much better than available from the active component commonly used of Flos Lonicerae or Folium Lonicerae.
Can will be prepared into curative by the sweroside that the present invention obtains by known method in the pharmaceutical field.Can also be with it separately or with oral administration or parenterai administrations such as pharmaceutically acceptable carrier, plasticizer, diluent.Can be made into powder, granule, tablet, capsule, syrup, skin ointments or injectable drug form especially.
Can select the human dose of active component of the present invention or sweroside according to active component absorption in vivo, inactivation rate and excretion rate, experimenter's age, sex and health, the order of severity of the disease for the treatment of etc.Preferably the adult is given active component or the sweroside of 1-200mg.According to the designation method administration, if desired, decide according to expert's suggestion.Can with medicine every day in the fixed interval administration several times, preferred every day 1-3 time.Can give described pharmaceutical composition by oral or non-oral mode.When through parenterai administration, can be with it by vein, muscle, rectum or percutaneous drug delivery.
Because the active component of stem of Caulis Lonicerae has good antiinflammatory and analgesic effect and ideal dissolubility, acute toxicity and blood stability, so they are very suitable for injectable drug.
Hereinafter the present invention has more specifically been described by the following examples.Yet the following example only is used to understand the present invention and they should not be regarded as the scope of the present invention that limits.
Embodiment
Embodiment 1: Radix Ophiopogonis each position drug effect
Gather the sample of Radix Ophiopogonis herb (Radix Ophiopogonis of band stem and leaf), Folium Lonicerae and stem of Caulis Lonicerae at Yeongcheon, the Gyeongsangbuk-do of Korea S in July, 1999.Sample dried in the shade and with the distilled water reflux, extract, 2.5 hours of 7 volumes and filter then.Collect residue subsequently and with the distilled water reflux, extract, of 7 volumes 2.5 hours.Filter the liquid obtain thus and merge, under reduced pressure, concentrate and filter once more, make its volume be about 2 times (v/w) of medical herbs weight in above-mentioned filtrate.Adding isopyknic water saturated n-butyl alcohol then also stirs this mixture 15 minutes with about 30rpm.After layer separates, filter the alcohol layer and under reduced pressure, concentrate and obtain the primary activity composition.Use polyamide (CAS NO.63428-83-1) to carry out column chromatography subsequently to obtain the purification fraction.Amount of resin is the sample of 5 volumes.50% (v/v) methanol of 2 volumes of eluting and methanol and obtain the secondary active component by substep gradient method eluting distilled water solvent then.By with Radix Ophiopogonis herb, stem of Caulis Lonicerae and the secondary delivery of active ingredients of Folium Lonicerae go into 4 hours 6-of fasting week ICR mice in age (body weight: 20-30g, n=6, SLC, Japan) tail vein and carry out the dropsy of ear test that Oleum Tiglii brings out.After 15 minutes, bring out inflammation with 2.5% Oleum Tiglii.After 4 hours, use the scale thickness gauge to measure the thickness of mice left side ear and auris dextra.As shown in table 1 by following equation 1 calculating inflammation rate and result.
Equation 1
Inflammation rate (%)=[thickness of the thickness of inflammation (right side) ear-normal (left side) ear]/[thickness of normal ear] * 100
Table 1
| Classification | Concentration (mg/kg) | Suppression ratio (%) |
| Radix Ophiopogonis herb | 1 | 27.6 |
| 3 | 29.7 | |
| 10 | 34.8 | |
| 25 | 33.6 | |
| 50 | 32.2 | |
| 100 | 30.4 | |
| Stem of Caulis Lonicerae | 3 | 30.2 |
| 30 | 39.0 | |
| Folium Lonicerae | 3 | 19.6 |
| 30 | 21.9 |
Just as shown in table 1, the active component of stem of Caulis Lonicerae shows best antiinflammatory and analgesic activity.
Embodiment 2: available from the drug effect of the active component of stem of Caulis Lonicerae relatively
Carry out the dropsy of ear test that Oleum Tiglii brings out as described in example 1 above.In addition, by medicine (marobiven, the secondary active component of the primary sector of stem of Caulis Lonicerae and stem of Caulis Lonicerae) administration being gone into 4 hours 6-of fasting ICR mice (body weight: 20-30g, n=6 in age in week, SLC, Japan) the tail vein carries out the dropsy of ear test that arachidonic acid brings out.After 15 minutes, bring out inflammation with 0.05% arachidonic acid.After about 1 hour, the thickness of measuring mice left side ear and auris dextra is also as shown in table 2 by equation 1 calculating suppression ratio and result.
Table 2
| Classification | Dosage (mg/kg) | Suppression ratio (%) | |
| CO* | AA** | ||
| Matched group (marobiven) | 50 | 21.0 | NT |
| 100 | 25.8 | NT | |
| 200 | 30.1 | NT | |
| The primary activity composition | 50 | 35.6 | NT |
| 100 | 36.2 | NT | |
| 200 | 38.0 | NT | |
| The secondary active component | 0.1 | 19.8 | 11.7 |
| 0.3 | 35.2 | 16.5 | |
| 3 | 38.0 | 26.3 | |
| 10 | 36.6 | 32.4 | |
| 30 | 37.1 | 48.7 | |
| * the result of the test NT of the dropsy of ear that brings out of the dropsy of ear test * * arachidonic acid that brings out of Oleum Tiglii: test | |||
Just as shown in table 2, do not comprise as this compounds of aromatics organic acid, tannin and flavonoid and have the active component content that is higher than the primary activity composition available from the secondary active component of stem of Caulis Lonicerae.
Embodiment 3: available from the drug effect of the active component of stem of Caulis Lonicerae relatively
Undertaken by replacing polyamide with polyvinylpyrrolidone resin (CAS NO.25249-54-1)
The step of embodiment 1.
Table 3
| Classification | Dosage (mg/kg) | Suppression ratio (%) | |
| CO* | AA** | ||
| Matched group (marobiven) | 50 | 20.2 | NT |
| 100 | 24.1 | NT | |
| 200 | 31.2 | NT | |
| The primary activity composition | 50 | 33.2 | NT |
| 100 | 35.1 | NT | |
| 200 | 37.5 | NT | |
| The secondary active component | 0.1 | 20.1 | 10.3 |
| 0.3 | 34.1 | 16.7 | |
| 3 | 39.7 | 24.9 | |
| 10 | 35.6 | 33.3 | |
| 30 | 36.4 | 49.6 | |
| * the result of the test NT of the dropsy of ear that brings out of the dropsy of ear test * * arachidonic acid that brings out of Oleum Tiglii: test | |||
Embodiment 4: the preparation of final active component and drug effect test
Under reduced pressure, concentrate the secondary active component of the stem of Caulis Lonicerae of preparation among the embodiment 1 and obtain powder.(S-50m or ODS-AQ12nm S-50m) carry out column chromatography again to described powder for YMC*GEL ODS-A 12nm, S-150m or ODS-AM 12nm to use the ODS resin.Use the resin of 3 volumes and eluting 20% (v/v) methanol and obtain final active component.
Carry out the dropsy of ear test that Oleum Tiglii brings out as described in example 1 above.
In addition, by being gone into 1 day ICR mice of fasting (body weight: 20-30g, n=8, SLC, Japan) tail vein, medicine (the last active component of marobiven and stem of Caulis Lonicerae) administration carries out the writhing test that acetic acid brings out.After 20 minutes, through peritoneal injection 0.7% acetic acid.After 15 minutes, the number of times of turning round body in 10 minutes is counted to calculate the inflammation suppression ratio.The result is as shown in table 4.
Table 4
| Classification | Dosage (mg/kg) | Suppression ratio (%) | |
| CO* | AA** | ||
| Matched group (marobiven) | 1 | 6.6 | 37.9 |
| 10 | 24.0 | 48.8 | |
| 100 | 29.8 | 56.5 | |
| Final active component | 0.1 | 29.6 | 62.1 |
| 1 | 34.8 | 68.4 | |
| 10 | 45.8 | 76.9 | |
| * the result of the test NT that turns round body that brings out of the dropsy of ear result of the test * * acetic acid that brings out of Oleum Tiglii: test | |||
Embodiment 5: active component content and drug effect test
From the high performance liquid chromatography (HPLC) that the final active component to preparation embodiment 1 and 4 carries out, active component content: sweroside=15.1-72.1wt% and loganin=13.9-41.4wt% have been identified.The sweroside of each sample and loganin content are as shown in table 5.Drug effect with the different final active component that change with acquisition time in the place of production is as shown in table 6.
Table 5: with different swerosides that change in the place of production and loganin content with acquisition time
| Month | Yeongcheon， Gyeongsangbuk-do(A) | Andong， Gyeongsangbuk-do(B) | Mount Taishan, China | Xinxiang, China |
| January | Lo:34.6 Sw:57.7 amounts to: 92.3 | Lo:38.3 Sw:55.4 amounts to: 93.7 | Lo:38.2 Sw:48.6 amounts to: 86.8 | Lo:31.4 Sw:59.2 amounts to: 90.6 |
| February | Lo:30.2 Sw:64.1 amounts to: 94.3 | Lo:32.3 Sw:62.1 amounts to: 94.4 | Lo:33.3 Sw:54.2 amounts to: 87.5 | Lo:28.6 Sw:63.3 amounts to: 91.9 |
| March | Lo:22.7 Sw:70.2 amounts to: 92.9 | Lo:26.1 Sw:67.6 amounts to: 93.7 | Lo:25.8 Sw:60.3 amounts to: 86.1 | Lo:20.5 Sw:72.1 amounts to: 92.6 |
| April | Lo:13.9 Sw:63.1 amounts to: 77.0 | Lo:15.9 Sw:60.1 amounts to: 76.0 | Lo:19.1 Sw:65.3 amounts to: 84.4 | Lo:14.2 Sw:69.7 amounts to: 83.9 |
| May | Lo:17.1 Sw:5 2.3 amounts to: 69.4 | Lo:14.2 Sw:55.7 amounts to: 69.9 | Lo:18.7 Sw:66.2 amounts to: 84.9 | Lo:14.9 Sw:55.2 amounts to: 70.1 |
| June | Lo:19.4 Sw:33.4 amounts to: 52.8 | Lo:16.2 Sw:38.2 amounts to: 54.4 | Lo:23.5 Sw:43.5 amounts to: 67.0 | Lo:17.4 Sw:42.6 amounts to: 60.0 |
| July | Lo:21.7 Sw:15.1 amounts to: 36.8 | Lo:25.3 Sw:17.5 amounts to: 42.8 | Lo:28.9 Sw:29.8 amounts to: 58.7 | Lo:22.4 Sw:35.2 amounts to: 57.6 |
| August | Lo:23.5 Sw:29.4 amounts to: 52.9 | Lo:27.0 Sw:32.7 amounts to: 59.7 | Lo:30.1 Sw:35.9 amounts to: 66.0 | Lo:32.1 Sw:36.4 amounts to: 68.5 |
| JIUYUE | Lo:25.3 Sw:47.6 amounts to: 72.9 | Lo:30.1 Sw:45.3 amounts to: 75.4 | Lo:33.6 Sw:42.5 amounts to: 76.1 | Lo:39.2 Sw:40.2 amounts to: 79.4 |
| October | Lo:28.7 Sw:52.2 amounts to: 80.9 | Lo:32.2 Sw:50.5 amounts to: 82.7 | Lo:33.8 Sw:48.2 amounts to: 82.0 | Lo:37.4 Sw:43.3 amounts to: 80.7 |
| November | Lo:39.6 Sw:54.3 amounts to: 93.9 | Lo:37.3 Sw:58.3 amounts to: 95.6 | Lo:38.0 Sw:54.6 amounts to: 92.6 | Lo:41.4 Sw:45.6 amounts to: 87.0 |
| December | Lo:36.2 Sw:56.8 amounts to: 93.0 | Lo:33.7 Sw:60.2 amounts to: 93.9 | Lo:35.2 Sw:58.3 amounts to: 93.5 | Lo:40.2 Sw:52.6 amounts to: 92.8 |
Lo: loganin; Sw: sweroside
Table 6
| Classification | Content (mg/kg) | Suppression ratio (%) | |
| CO* | AA** | ||
| Matched group (marobiven) | 10 | 25.6 | 46.9 |
| 100 | 28.8 | 56.8 | |
| Yeongcheon, July Lo:21.7, Sw:15.1 amounts to: 36.8 | 1 | 37.2 | 70.2 |
| 10 | 46.3 | 75.1 | |
| Andong, July Lo:25.3, Sw:17.5 amounts to: 42.8 | 1 | 40.3 | 72.2 |
| 10 | 51.2 | 84.3 | |
| Xinxiang, July Lo:22.4, Sw:35.2 amounts to: 57.6 | 1 | 49.8 | 78.8 |
| 10 | 52.6 | 85.6 | |
| Mount Taishan, JIUYUE Lo:33.6, Sw:42.5 amounts to: 76.1 | 1 | 52.1 | 82.9 |
| 10 | 52.4 | 85.5 | |
| Andong, November Lo:37.3, Sw:58.3 amounts to: 95.6 | 1 | 53.4 | 84.6 |
| 10 | 53.2 | 87.7 | |
* the Oleum Tiglii dropsy of ear result of the test of bringing out
The writhing test result that * acetic acid brings out
Embodiment 6: the hemolytic test of final active component
The syringe that use is handled with heparin is gathered 20mL blood from tame rabbit heart.With about 10 minutes of centrifugal blood.The decantation supernatant also dilutes residue with the injection normal saline solution of 10 volumes.After mixing by slow jolting, with the blood of 0.5mL dilution and each medicine of 0.5mL embodiment 1 (the final active component of stem of Caulis Lonicerae and stem of Caulis Lonicerae, Folium Lonicerae and Radix Ophiopogonis herb the primary activity composition) and the final active component of embodiment 4 put into test tube (also having prepared normal saline solution and distilled water (100% haemolysis) matched group).Test tube is incubated 15 minutes and placed then under the room temperature 45 minutes in the bath that remains under 37 ℃.Finally after centrifugal 2 minutes, analyze the upper strata at the 540nm place with 2500rpm.
Table 7
| Classification | Haemolysis (%) | Standard deviation |
| Matched group (injection normal saline solution) | 0.73 | 0.17 |
| Final active component, 5 * 10 -4g/ml | 0.69 | 0.10 |
| Final active component, 1.5 * 10 -3g/ml | 0.73 | 0.11 |
| Final active component, 5 * 10 -3g/ml | 0.74 | 0.88 |
| Stem of Caulis Lonicerae, 5 * 10 -3g/ml | 15.2 | 0.20 |
| Folium Lonicerae, 5 * 10 -3g/ml | 35.1 | 0.15 |
| Radix Ophiopogonis herb, 5 * 10 -3g/ml | 23.0 | 0.45 |
Embodiment 7: the preparation of sweroside
Use the octadecylsilane resin that the final active component of preparation among the embodiment 4 is carried out column chromatography to separate the sweroside of being represented by following chemical formula 1:
Embodiment 8: the mensuration of sweroside antiinflammatory action
Carry out the dropsy of ear test that Oleum Tiglii brings out by the sweroside administration being gone into 4 hours 6-of fasting week ICR mice in age (body weight: 20-30g, n=6, SLC, Japan) tail vein.After 15 minutes, bring out inflammation with 2.5% Oleum Tiglii.After 4 hours, use the scale thickness gauge to measure the thickness of mice left side ear and auris dextra.As shown in table 8 by equation 1 calculating inflammation rate and result.
The drug effect of oral administration is as shown in table 9.
Table 8
| Classification | Dosage (mg/kg) | Suppression ratio (%) |
| Sweroside | 0.1 | 49.8 |
| 1 | 56.2 | |
| 10 | 65.7 |
Table 9
| Classification | Dosage (mg/kg) | Suppression ratio (%) |
| Sweroside | 1 | 31.9 |
| 10 | 43.1 | |
| 100 | 57.8 |
In addition, carry out the dropsy of ear test that arachidonic acid brings out by the sweroside administration being gone into 4 hours 6-of fasting week ICR mice in age (body weight: 20-30g, n=6, SLC, Japan) tail vein.After 15 minutes, bring out inflammation with 0.05% arachidonic acid.After 1 hour, the thickness of measuring mice left side ear and auris dextra is also as shown in table 10 by equation 1 calculating suppression ratio and result.The drug effect of oral administration is as shown in table 9.
Table 10
| Classification | Dosage (mg/kg) | Suppression ratio (%) |
| Sweroside | 0.1 | 48.3 |
| 1 | 55.1 | |
| 10 | 69.1 |
Table 11
| Classification | Dosage (mg/kg) | Suppression ratio (%) |
| Sweroside | 1 | 29.0 |
| 10 | 34.7 | |
| 100 | 45.7 |
Embodiment 9: the mensuration of sweroside analgesic effect
Carry out the writhing test that acetic acid brings out by the sweroside administration being gone into 1 day ICR mice of fasting (body weight: 20-30g, n=8, SLC, Japan) tail vein.After 20 minutes, through peritoneal injection 0.7% acetic acid.After 15 minutes, the number of times of turning round body in 10 minutes is counted to calculate the inflammation suppression ratio.The result is as shown in Table 12.The drug effect of oral administration is as shown in table 13.
Table 12
| Classification | Dosage (mg/kg) | Suppression ratio (%) |
| Sweroside | 0.1 | 74.6 |
| 1 | 86.4 | |
| 10 | 89.7 |
Table 13
| Classification | Dosage (mg/kg) | Suppression ratio (%) |
| Sweroside | 1 | 65.9 |
| 10 | 79.1 | |
| 100 | 87.9 |
Embodiment 10: toxicity test
Respectively with the stem of Caulis Lonicerae active component of 1.0g/kg, 1.5g/kg and 2.0g/kg consumption and sweroside tail intravenously administrable (body weight: 120-170g, each dosage has 5 male and female rats, SLC, Japan) by 4 hours SD rat of fasting.At first rat was observed 30 minutes and detected by an unaided eye in 30 minutes at interval then.After the administration mortality rate, general symptom and body weight are changed 2 weeks of observation.Carry out entity and dissect any organs abnormality that exists with evaluation.
The oral administration fatal dose of stem of Caulis Lonicerae active component and sweroside is not all above 5.0g/kg (observing dead rat), and the intravenous injection fatal dose is not all above 2.0g/kg (observing dead rat).When intravenous injection 2.0g/kg, rat shows respiratory count increase and movable the minimizing, continues about 10 minutes, rapidly recovery.Do not observe other symptom and the change of body weight does not take place because of administration.The entity anatomical results does not show abnormality, and is identical with the situation of matched group.
Respectively 50,100 and 150mg/kg dosage under local toxicity test do not demonstrate and give the difference of the group of normal saline solution.Do not observe such as tissue necrosis or this class toxicity of inflammation.
Preparation embodiment 1: the preparation of tablet
Stem of Caulis Lonicerae active component or sweroside are made the tablet with following composition:
Active component 160mg
Light body anhydrous silicic acid 20mg
Corn starch 87mg
Crystalline cellulose 72mg
Hydroxyacetic acid (glyconate) Starch Sodium 60mg
Magnesium stearate 6mg
Amount to 672mg
Preparation embodiment 2: the preparation of syrup
Stem of Caulis Lonicerae active component or sweroside are made the syrup with following composition:
Active component 4,000mg
Methyl parahydroxybenzoate (5% alcoholic solution) 60mg
Propyl p-hydroxybenzoate (5% alcoholic solution) 40mg
Sodium benzoate (5% solution) 100mg
Fructus Musae powder (10% solution) 600mg
D-sorbitol 140,000mg
Distilled water 196mL
Preparation embodiment 3: the preparation of injection
Stem of Caulis Lonicerae active component or sweroside are made the injection with following composition:
Injection ampoule: active component 20mg
Mannitol 60mg
The corresponding solvent sample:
Injection normal saline solution 2000mg
Amount to 2080mg
Preparation embodiment 4: the preparation of injection
Stem of Caulis Lonicerae active component or sweroside are made the injection with following composition:
Injection ampoule: active component 50mg
KH
2(PO
4) 8.5mg
Injection normal saline solution 3000mg
Amount to 3058.5mg
Preparation embodiment 5: the preparation of injection
Stem of Caulis Lonicerae active component or sweroside are made the injection with following composition:
Injection ampoule: active component 100mg
Mannitol 300mg
KH
2(PO
4) 17mg
Injection normal saline solution 3000mg
Amount to 3417mg
Preparation embodiment 6: the preparation of ointment medicine
Stem of Caulis Lonicerae active component or sweroside are made the ointment medicine with following composition:
Active component 5g
Liquid paraffin 10g
Antimonial lead 9g
Ethanol 8g
Dehydrating sorbitol monooleate 2g
Polysorbate 4g
Propyl p-hydroxybenzoate 0.05g
Methyl parahydroxybenzoate 0.1g
Concentrated glycerin 10g
The pure water capacity
As mentioned above, the present invention has the dissolubility and the blood stability of remarkable increase than those active component commonly used available from the active component of stem of Caulis Lonicerae.In addition, confirm that they have good pain relieving and antiinflammatory action, safety and stability.In addition, the present invention has very good drug effect and does not almost demonstrate toxicity available from the sweroside of stem of Caulis Lonicerae, is particularly suitable for antiinflammatory and analgesic thus.
Although specifically described the present invention, it will be understood by those skilled in the art that and to carry out various modifications and replacement and can not break away from the spirit and scope of the invention of determining as the claim that awaits the reply it with reference to preferred embodiment.
Claims (1)
1. antiinflammatory and analgesic comprise the sweroside that following chemical formula 1 is represented:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020020055106A KR100834966B1 (en) | 2002-09-11 | 2002-09-11 | Manufacturing method of fraction from stem of Lonicera japonica Thunb. and injection drug comprising the fraction |
| KR1020020055106 | 2002-09-11 | ||
| KR1020020058494 | 2002-09-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB03823484XA Division CN100544744C (en) | 2002-09-11 | 2003-09-08 | Method, its application in antiinflammatory and analgesic of extraction and purification active component from stem of Caulis Lonicerae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1951395A true CN1951395A (en) | 2007-04-25 |
Family
ID=37327043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101320479A Pending CN1951395A (en) | 2002-09-11 | 2003-09-08 | Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR100834966B1 (en) |
| CN (1) | CN1951395A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100554079B1 (en) * | 2002-09-23 | 2006-02-22 | 학교법인 경희대학교 | Lonicera japonica thunb |
| CN114933662B (en) * | 2022-05-27 | 2023-07-25 | 山东中医药大学 | Honeysuckle stem polysaccharide and preparation method and application thereof |
-
2002
- 2002-09-11 KR KR1020020055106A patent/KR100834966B1/en not_active IP Right Cessation
-
2003
- 2003-09-08 CN CNA2006101320479A patent/CN1951395A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040023392A (en) | 2004-03-18 |
| KR100834966B1 (en) | 2008-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100544744C (en) | Method, its application in antiinflammatory and analgesic of extraction and purification active component from stem of Caulis Lonicerae | |
| CN101342229B (en) | Composition of Canton love-pea vine extract, preparation method and pharmaceutical use | |
| CN101301401A (en) | Camellia effective ingredients and extracting method and use thereof | |
| CN103156869A (en) | Sanggenone C and sanggenone D extracted from morus plants and new medicine application of composition | |
| US20120308677A1 (en) | Pharmaceutical Composition for Preventing and Treating Inflammatory Diseases Containing an Ethyl Acetate Fraction of Dried Extract of Trachelospermi Caulis as an Active Ingredient, and Method for Producing the Fraction | |
| CN102526141B (en) | Pterocephalus hookeri heck total iridoid glycoside extract and preparation method and application thereof | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN1330328C (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| Dora et al. | Punarnava (Boerhavia diffusa): A promising indigenous herbal drug and its effect on different disease conditions | |
| CN101588810B (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| CN1951395A (en) | Extraction and purification method of active constituents from stem of lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug | |
| CN111374970B (en) | Composition with anti-colitis activity and application thereof | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| Sirisha et al. | A review on herbal diuretics | |
| CN100528170C (en) | Mangiferin preparation and production thereof | |
| KR100672036B1 (en) | Asthma Therapeutics using Lonicera japonica extracts | |
| Odimegwu et al. | Anti-respiratory syncytial virus agents from phytomedicine | |
| CN114767695B (en) | Extraction method and application of allium fistulosum lactone | |
| Pandey et al. | Pharmacological activities of Calendula officinalis | |
| CN101974012A (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
| CN101147757A (en) | Traditional Chinese medicine for treating chronic hepatitis B and its preparation process | |
| Uniyal et al. | ANTI–CANCER DRUGS FROM UP HIMALAYA | |
| Makwana et al. | Exploration of bioactive compounds in Operculina Turpethum L. | |
| CN114949025A (en) | Senecio scandens gel for treating diabetic foot and nursing after hemorrhoid operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1105356 Country of ref document: HK |
|
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20070425 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1105356 Country of ref document: HK |